Acumen Pharmaceuticals, Inc. ABOS
Institutional shares held
36.2 Million
11.6K
calls
0
puts
Total value of holdings
$64.5M
$20K
calls
$0
puts
Market Cap
$72.1M
40,503,100
Shares Out.
Institutional ownership
89.48%
# of Institutions
72
We take great care to ensure that the data presented and summarized in this overview for Acumen Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABOS
View all-
Ra Capital Management, L.P. Boston, MA14.9MShares$26.6 Million0.46% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$6.08 Million2.33% of portfolio
-
Franklin Resources Inc San Mateo, CA2.31MShares$4.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.84 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$2.94 Million0.0% of portfolio
-
Knollwood Investment Advisory, LLC Hunt Valley, MD1.63MShares$2.9 Million0.25% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL940KShares$1.67 Million0.01% of portfolio
-
Adar1 Capital Management, LLC Austin, TX891KShares$1.59 Million0.14% of portfolio
-
Laurion Capital Management LP New York, NY867KShares$1.54 Million0.03% of portfolio
-
Pathstone Holdings, LLC Englewood, NJ859KShares$1.53 Million0.01% of portfolio
Latest Institutional Activity in ABOS
Top Purchases
Top Sells
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Transactions at ABOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2026
|
James J. Doherty President and CDO |
SELL
Open market or private sale
|
Direct |
6,467
-10.69%
|
$6,467
$1.82 P/Share
|
|
Jan 07
2026
|
Amy Schacterle Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
1,097
-12.47%
|
$1,097
$1.98 P/Share
|
|
Jan 07
2026
|
James J. Doherty President and CDO |
SELL
Open market or private sale
|
Direct |
1,700
-2.73%
|
$1,700
$1.99 P/Share
|
|
Jan 07
2026
|
Russell Barton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,700
-1.32%
|
$1,700
$1.99 P/Share
|
|
Jan 07
2026
|
Derek M Meisner Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
11,770
-4.07%
|
$11,770
$1.99 P/Share
|
|
Jan 07
2026
|
Daniel Joseph O Connell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,755
-5.74%
|
$37,755
$1.99 P/Share
|
|
Jan 07
2026
|
Matt Zuga CFO & Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,805
-1.31%
|
$5,805
$2.0 P/Share
|
|
Jan 06
2026
|
Russell Barton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,618
-2.74%
|
$3,618
$1.97 P/Share
|
|
Jan 06
2026
|
Derek M Meisner Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
10,898
-3.53%
|
$10,898
$1.97 P/Share
|
|
Jan 06
2026
|
Daniel Joseph O Connell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,102
-0.77%
|
$5,102
$1.97 P/Share
|
|
Jan 06
2026
|
Eric Siemers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,834
-4.11%
|
$6,834
$1.97 P/Share
|
|
Jan 06
2026
|
Matt Zuga CFO & Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,100
-2.24%
|
$5,100
$1.97 P/Share
|
|
Jan 05
2026
|
Russell Barton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,000
-2.94%
|
$4,000
$1.96 P/Share
|
|
Jan 05
2026
|
Derek M Meisner Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
4,000
-2.48%
|
$4,000
$1.96 P/Share
|
|
Jan 05
2026
|
Daniel Joseph O Connell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,649
-0.7%
|
$4,649
$1.97 P/Share
|
|
Jan 05
2026
|
Eric Siemers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-2.35%
|
$4,000
$1.96 P/Share
|
|
Jan 05
2026
|
Matt Zuga CFO & Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,000
-1.73%
|
$4,000
$1.96 P/Share
|
|
Jun 04
2025
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
12,800
+50.0%
|
-
|
|
Jun 04
2025
|
Laura Stoppel Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,800
+50.0%
|
-
|
|
Jun 04
2025
|
Kimberlee C Drapkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,800
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
89.6K
Shares
From
7
Insiders
| Grant, award, or other acquisition | 89.6K shares |
|---|
Sell / Disposition
174K
Shares
From
7
Insiders
| Open market or private sale | 174K shares |
|---|